IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 121 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  
  In this article
    Abstract
    References

 Article Access Statistics
    Viewed25995    
    Printed651    
    Emailed60    
    PDF Downloaded0    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 
ORIGINAL ARTICLE
Year : 2003  |  Volume : 69  |  Issue : 1  |  Page : 25-26

Treatment of schamberg's disease with pentoxifylline - therapeutic trial


Department of Dermatology and STD UCMS & GTB Hospital, Shahdara, Delhi - 110 095

Correspondence Address:
Department of Dermatology and STD UCMS & GTB Hospital, Shahdara, Delhi - 110 095

   Abstract 

Twenty patients with Schamberg's disease were started on pentoxifylline (400 mg once daily) for a period of 8 weeks. Improvement was assessed at 2 weekly intervals by two observers independently and graded as mild (<25%, moderate (25-50%) and marked (>50%). Marked improvement was observed in 10/20(50%) patients. We conclude that pentoxifylline should be considered as first line therapy in all patients with Schamberg's disease

How to cite this article:
Gandhi V, Singal A, Sachdeva B, Bhattacharya S N. Treatment of schamberg's disease with pentoxifylline - therapeutic trial. Indian J Dermatol Venereol Leprol 2003;69:25-6


How to cite this URL:
Gandhi V, Singal A, Sachdeva B, Bhattacharya S N. Treatment of schamberg's disease with pentoxifylline - therapeutic trial. Indian J Dermatol Venereol Leprol [serial online] 2003 [cited 2014 Aug 22];69:25-6. Available from: http://www.ijdvl.com/text.asp?2003/69/1/25/5815


Introduction
Schamberg's disease (Progressive pigmented purpuric dermatoses) is a capillarits of unknown etiology characterized by orange to fawn-colored macules and plaques usually localized to the lower limbs.[1] Characteristic 'cayenne pepper' spots due to hemosiderin deposition in the skin are seen at the periphery of the lesions.[2] Histopathology consists of a superficial lymphocytic perivascular inflammation with increased capillaries and siderophages in the upper dermis.[3] The disease follows a chronic course with spontaneous clearance in a few cases. Treatment modalities which have been used include topical and systemic corticosteroids, vitamin C and topical and systemic anti inflammatory agents. Pentoxifylline, a methylxanthine derivatice, has been used successfully in treatment of various types of vasculitides, specially leucocytoclastic vasculitis. A report of its successful use in Schamberg's disease' prompted us to conduct a larger trial.
Materials and Methods
Twenty patients presenting with characteristic lesions of Schamberg's disease confirmed on histopathology were included in the trial. Pentoxifylline was started in a dose of 400 mg once daily. No other topical or systemic treatment was given during the study period. Response to treatment was assessed independently by two observers at 2 week intervals and graded as percentage of clearance of lesions. Improvement was graded as mild (<25%), moderate (25-50%) and marked (>50%).
Results
The improvement as assessed by two different observers at 2 weekly intervals is as shown in [Table - 1].
Discussion
Successful treatment in Schamberg's disease presents a veritable challenge to the treating physician. Spontaneous clearance, though well documented, occurs uncommonly. Commonly recommended treatment modalities include physical measures aided at reducing venous pressure (graduated compression stocking), topical and systemic steroids, ascorbic acid, topical and systemic anti -1nflamatory agents and griseofulvin. Pentoxifylline, a methylxanthine derivative, has multiple effects at cellular level including potent rheological properties. This results in increased erythrocyte deformability, immunomodulator action by modifying cytokine profile and antifiroblastic action.[4] Specially interesting is its role.
The improvement as assessed by two different observers at 2 weekly intervals is as shown in [Table - 1] in cutaneous vasculitides such as rheumatoid, urticarial, leucocytoclastic and livedoid vasculitis. Recently, Kano et al have demonstrated a decrease in expression of ICAM-I on endothelial cells of blood vessels of lesional skin following successful treatment with pentoxifylline.[3] This results in decreased exudation of inflammatory cells from capillaries into the sorrounding perivascular tissue. Moreover, pentoxifylline inhibits synthesis and release of TNF-a.[5],[6] This results in reduced TNFa mediated extravasation from the capillaries. Our preliminary study shows marked improvement in 10/20 (50%) patients after 8 weeks of treatment. Pentoxifylline is an economical and easily available drug which is devoid of serious side effects. So we conclude that pentoxifylline should be considered as first line therapy in Schamberg's disease. 

   References Top

1.Faria DT, Fivenson DP, Green H. Peripheral vascular diseases. In: Dermatology; Eds Moshello SL, Hurley HJ, 3'd edition, WB Saunders Company 1992; 1177-1178.  Back to cited text no. 1    
2.Champion RH. Purpura. In: Textbook of Dermatology. Eds Champion RH, Burton JL, Burns DA & Breathnach SM, Vol III, 6th ed. Blackwell Scientific Publications 1998; 2149-2151.  Back to cited text no. 2    
3.Kano Y, Hiroyama K, Shiohra T Successful treatment of Schamberg's disease with pentoxifylline. J Am Acad Dermatol 1997; 36: 827-830.  Back to cited text no. 3    
4.Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-621.  Back to cited text no. 4    
5.Ely H. Is pentoxifylline the drug of the decade? J Am Acad Dermatol 1994; 30: 603-640.  Back to cited text no. 5    
6.Schwarz A, Arragne Y, Simson M, et al. Pentoxifylline suppresses UVB induced cutokine release by keratinocytes (abstract). J Invest Dermatol 1993;101:388.  Back to cited text no. 6    

 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Medknow